These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34043126)

  • 1. Possible role of rice bran extract in microglial modulation through PPAR-gamma receptors in alzheimer's disease mice model.
    El-Din SS; Abd Elwahab S; Rashed L; Fayez S; Aboulhoda BE; Heikal OA; Galal AF; Nour ZA
    Metab Brain Dis; 2021 Oct; 36(7):1903-1915. PubMed ID: 34043126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rice Bran Extract Protected against LPS-Induced Neuroinflammation in Mice through Targeting PPAR-γ Nuclear Receptor.
    Abd El Fattah MA; Abdelhamid YA; Elyamany MF; Badary OA; Heikal OA
    Mol Neurobiol; 2021 Apr; 58(4):1504-1516. PubMed ID: 33205365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malva parviflora extract ameliorates the deleterious effects of a high fat diet on the cognitive deficit in a mouse model of Alzheimer's disease by restoring microglial function via a PPAR-γ-dependent mechanism.
    Medrano-Jiménez E; Jiménez-Ferrer Carrillo I; Pedraza-Escalona M; Ramírez-Serrano CE; Álvarez-Arellano L; Cortés-Mendoza J; Herrera-Ruiz M; Jiménez-Ferrer E; Zamilpa A; Tortoriello J; Pedraza-Alva G; Pérez-Martínez L
    J Neuroinflammation; 2019 Jul; 16(1):143. PubMed ID: 31291963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes.
    Zhao Q; Wu X; Yan S; Xie X; Fan Y; Zhang J; Peng C; You Z
    J Neuroinflammation; 2016 Oct; 13(1):259. PubMed ID: 27716270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice.
    Yamanaka M; Ishikawa T; Griep A; Axt D; Kummer MP; Heneka MT
    J Neurosci; 2012 Nov; 32(48):17321-31. PubMed ID: 23197723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.
    Mandrekar-Colucci S; Karlo JC; Landreth GE
    J Neurosci; 2012 Jul; 32(30):10117-28. PubMed ID: 22836247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits.
    Kummer MP; Schwarzenberger R; Sayah-Jeanne S; Dubernet M; Walczak R; Hum DW; Schwartz S; Axt D; Heneka MT
    Mol Neurobiol; 2015 Apr; 51(2):661-71. PubMed ID: 24838579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease.
    Gupta R; Gupta LK
    Pharmacol Biochem Behav; 2012 Aug; 102(2):184-90. PubMed ID: 22503969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.
    Skerrett R; Pellegrino MP; Casali BT; Taraboanta L; Landreth GE
    J Biol Chem; 2015 Aug; 290(35):21591-602. PubMed ID: 26163517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglial forkhead box O3a deficiency attenuates LPS-induced neuro-inflammation and depressive-like behaviour through regulating the expression of peroxisome proliferator-activated receptor-γ.
    Wang R; Ji L; Yuan S; Liu X; Liang Z; Chen W; Wang B; Hu S; Liu Z; Zeng Z; Song Y; Wu T; Chen B
    Br J Pharmacol; 2024 Oct; 181(20):3908-3925. PubMed ID: 38881194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
    Heneka MT; Sastre M; Dumitrescu-Ozimek L; Hanke A; Dewachter I; Kuiperi C; O'Banion K; Klockgether T; Van Leuven F; Landreth GE
    Brain; 2005 Jun; 128(Pt 6):1442-53. PubMed ID: 15817521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of β-amyloid animal model of Alzheimer's disease.
    Prakash A; Kumar A
    Neurotox Res; 2014 May; 25(4):335-47. PubMed ID: 24277156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis.
    Cheng H; Shang Y; Jiang L; Shi TL; Wang L
    Int J Neurosci; 2016; 126(4):299-307. PubMed ID: 26001206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-β and cerebrovascular pathology.
    Papadopoulos P; Rosa-Neto P; Rochford J; Hamel E
    PLoS One; 2013; 8(7):e68612. PubMed ID: 23874687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.
    Liu J; Wang LN; Jia JP
    Drugs Aging; 2015 Jan; 32(1):57-65. PubMed ID: 25504005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation.
    Biechele G; Blume T; Deussing M; Zott B; Shi Y; Xiang X; Franzmeier N; Kleinberger G; Peters F; Ochs K; Focke C; Sacher C; Wind K; Schmidt C; Lindner S; Gildehaus FJ; Eckenweber F; Beyer L; von Ungern-Sternberg B; Bartenstein P; Baumann K; Dorostkar MM; Rominger A; Cumming P; Willem M; Adelsberger H; Herms J; Brendel M
    Theranostics; 2021; 11(18):8964-8976. PubMed ID: 34522221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature.
    Alhowail A; Alsikhan R; Alsaud M; Aldubayan M; Rabbani SI
    Drug Des Devel Ther; 2022; 16():2919-2931. PubMed ID: 36068789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease.
    Machado MMF; Bassani TB; Cóppola-Segovia V; Moura ELR; Zanata SM; Andreatini R; Vital MABF
    Pharmacol Rep; 2019 Aug; 71(4):556-564. PubMed ID: 31132685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt.
    Xing B; Xin T; Hunter RL; Bing G
    J Neuroinflammation; 2008 Jan; 5():4. PubMed ID: 18205920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.
    Sato T; Hanyu H; Hirao K; Kanetaka H; Sakurai H; Iwamoto T
    Neurobiol Aging; 2011 Sep; 32(9):1626-33. PubMed ID: 19923038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.